0000-0002-3297-5801

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2020 | 2019 | 2018 | 2017

2020

Volz, Nico B; Hanna, Diana L; Stintzing, Sebastian; Zhang, Wu; Yang, Dongyun; Cao, Shu; Ning, Yan; Matsusaka, Satoshi; Sunakawa, Yu; Berger, Martin D.; Cremolini, Chiara; Loupakis, Fotios; Falcone, Alfredo; Lenz, Heinz-Josef (2020). Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 12(10) MDPI AG 10.3390/cancers12102947

2019

Tokunaga, Ryuma; Cao, Shu; Naseem, Madiha; Battaglin, Francesca; Lo, Jae Ho; Arai, Hiroyuki; Loupakis, Fotios; Stintzing, Sebastian; Puccini, Alberto; Berger, Martin D.; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Salhia, Bodour; Mumenthaler, Shannon M; Weisenberger, Daniel J; Liang, Gangning; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo; ... (2019). AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. International journal of cancer, 145(8), pp. 2082-2090. Wiley-Blackwell 10.1002/ijc.32261

2018

Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Cremolini, Chiara; Lonardi, Sara; Bergamo, Francesca; Ning, Yang; Yamamoto, Noriko; Okazaki, Satoshi; Berger, Martin Dave; Miyamoto, Yuji; Gopez, Roel; Barzi, Afsaneh; Yamaguchi, Toshiharu; Stintzing, Sebastian; Heinemann, Volker; Loupakis, Fotios; Falcone, Alfredo; ... (2018). Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. The pharmacogenomics journal, 18(5), pp. 623-632. Nature Publishing Group 10.1038/s41397-018-0030-8

2017

Matsusaka, S; Cao, S; Hanna, D L; Sunakawa, Y; Ueno, M; Mizunuma, N; Zhang-Wu, Xiaxia; Yang, D; Ning, Y; Stintzing, S; Sebio, A; Stremitzer, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, Martin Dave; El-Khoueiry, R; Mendez, A; Ichikawa, W; Loupakis, F; ... (2017). CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics journal, 17(6), pp. 543-550. Nature Publishing Group 10.1038/tpj.2016.59

Provide Feedback